Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials

BACKGROUND: Suvemcitug (BD0801), a novel humanized rabbit monoclonal antibody against vascular endothelial growth factor, has demonstrated promising antitumor activities in preclinical studies. PATIENTS AND METHODS: The phase Ia/b trials investigated the safety and tolerability and antitumor activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, C., Ji, D., Ding, Y., Zhang, Y., Song, W., Liu, L., Wu, Y., Song, L., Feng, X., Zhang, J., Cao, J., Xu, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265603/
https://www.ncbi.nlm.nih.gov/pubmed/37178668
http://dx.doi.org/10.1016/j.esmoop.2023.101540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265603/
https://www.ncbi.nlm.nih.gov/pubmed/37178668
http://dx.doi.org/10.1016/j.esmoop.2023.101540

Ejemplares similares